Literature DB >> 21490357

The FREEDOM trial: Is family medicine ready for biologic therapies?

Alan D Bell, Benjamin R Bell.   

Abstract

Year:  2011        PMID： 21490357      PMCID： PMC3076475     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  14 in total

Review 1.  The crippling consequences of fractures and their impact on quality of life.

Authors:  C Cooper
Journal:  Am J Med       Date:  1997-08-18       Impact factor: 4.965

Review 2.  Identification of vertebral fractures: an update.

Authors:  L Ferrar; G Jiang; J Adams; R Eastell
Journal:  Osteoporos Int       Date:  2005-05-03       Impact factor: 4.507

3.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Authors:  Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

4.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

5.  Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.

Authors:  Jacques P Brown; Richard L Prince; Chad Deal; Robert R Recker; Douglas P Kiel; Luiz H de Gregorio; Peyman Hadji; Lorenz C Hofbauer; Jose M Alvaro-Gracia; Huei Wang; Matthew Austin; Rachel B Wagman; Richard Newmark; Cesar Libanati; Javier San Martin; Henry G Bone
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

Review 6.  Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 1. Introduction.

Authors:  D A Hanley; R G Josse
Journal:  CMAJ       Date:  1996-10-01       Impact factor: 8.262

7.  The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study.

Authors:  A Papaioannou; C C Kennedy; G Ioannidis; Y Gao; A M Sawka; D Goltzman; A Tenenhouse; L Pickard; W P Olszynski; K S Davison; S Kaiser; R G Josse; N Kreiger; D A Hanley; J C Prior; J P Brown; T Anastassiades; J D Adachi
Journal:  Osteoporos Int       Date:  2007-10-09       Impact factor: 4.507

8.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Authors:  Paul D Miller; Michael A Bolognese; E Michael Lewiecki; Michael R McClung; Beiying Ding; Matthew Austin; Yu Liu; Javier San Martin
Journal:  Bone       Date:  2008-04-26       Impact factor: 4.398

9.  Denosumab in postmenopausal women with low bone mineral density.

Authors:  Michael R McClung; E Michael Lewiecki; Stanley B Cohen; Michael A Bolognese; Grattan C Woodson; Alfred H Moffett; Munro Peacock; Paul D Miller; Samuel N Lederman; Charles H Chesnut; Douglas Lain; Alan J Kivitz; Donna L Holloway; Charlie Zhang; Mark C Peterson; Pirow J Bekker
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

10.  The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  J D Adachi; G Ioannidis; L Pickard; C Berger; J C Prior; L Joseph; D A Hanley; W P Olszynski; T M Murray; T Anastassiades; W Hopman; J P Brown; S Kirkland; C Joyce; A Papaioannou; S Poliquin; A Tenenhouse; E A Papadimitropoulos
Journal:  Osteoporos Int       Date:  2003-08-12       Impact factor: 4.507
View more
  1 in total

Review 1.  A Review on the Role of Denosumab in Fracture Prevention.

Authors:  Kok-Lun Pang; Nie Yen Low; Kok-Yong Chin
Journal:  Drug Des Devel Ther       Date:  2020-10-01       Impact factor: 4.162
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.